Human papillomavirus testing for primary cervical cancer screening

References

• GLOBOCAN 2002, Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancer Base No. 5 (Version 2.0). Ferlay J, Bray F, Pisani P, Parkin DM (Eds). IARC Press, Lyon, France (2004).
   Google Scholar
• Arbyn M, Primic-Zakelj M, Raifu AO et al. The burden of cervical cancer in south-east Europe at the beginning of the 21st century. Coll. Antropol.31(Suppl. 2), 7–10 (2007).
   PubMedGoogle Scholar
• IARC Working Group on the Evaluation of Cancer Preventive Strategies. Cervix cancer screening. In: IARC Handbooks of Cancer Prevention (Volume 10). IARC Press, Lyon, France (2005).
   Google Scholar
• Arblaster L, Lambert M, Entwistle V et al. A systematic review of the effectiveness of health service interventions aimed at reducing inequalities in health. J. Health Serv. Res. Policy1(2), 93–103 (1996).
   PubMedGoogle Scholar
• WHO Comprehensive Cervical Cancer Control. A guide to essential practice. WHO Press, Geneva, Switzerland (2006).
   Google Scholar
• European Commission. European Guidelines for Quality Assurance in Cervical Cancer Screening (2nd Edition). Arbyn M, Anttila A, Jordan J et al. (Eds). Office for Official Publications of the European Communities, Luxembourg (2008).
   Google Scholar
• Nanda K, McCrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med.132(10), 810–819 (2000).
   PubMed Web of Science ®Google Scholar
• Karnon J, Peters J, Platt J et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol. Assess.8(20), 1–78 (2004).
   Web of Science ®Google Scholar
• International Agency for Research and Cancer (IARC) Working Group. Human Papillomaviruses (Volume 64). WHO, IARC Press, Lyon, France (1995).
   Google Scholar
• Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol.189(1), 12–19 (1999).
   PubMed Web of Science ®Google Scholar
• IARC monographs on the evaluation of carcinogenic risks to humans. In: Human Papillomaviruses (Volume 90). IARC Press, Lyon, France 1–689 (2007).
   Google Scholar
• Clifford GM, Smith JS, Plummer M et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br. J. Cancer88(1), 63–73 (2003).
   PubMed Web of Science ®Google Scholar
• Schlecht NF, Platt RW, Duarte-Franco E et al. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J. Natl Cancer Inst.95(17), 1336–1343 (2003).
   PubMedGoogle Scholar
• Bosch FX, Lorincz A, Muñoz N et al. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol.55(4), 244–265 (2002).
   PubMed Web of Science ®Google Scholar
• Syrjänen KJ. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur. J. Obstet. Gynecol. Reprod. Biol.65(1), 45–53 (1996).
   PubMed Web of Science ®Google Scholar
• Holowaty P, Miller AB, Rohan T et al. Natural history of dysplasia of the uterine cervix. J. Natl Cancer Inst.91(3), 252–258 (1999).
   PubMedGoogle Scholar
• Lörincz AT. Molecular methods for the detection of human papillomavirus infection. Obstet. Gynecol. Clin. North Am.23(3), 707–730 (1996).
   PubMed Web of Science ®Google Scholar
• Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis. Markers23(4), 273–281 (2007).
   PubMed Web of Science ®Google Scholar
• Kraus I, Molden T, Holm R et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J. Clin. Microbiol.44(4), 1310–1317 (2006).
   PubMed Web of Science ®Google Scholar
• von Knebel Doeberitz M. New molecular tools for efficient screening of cervical cancer. Dis. Markers17(3), 123–128 (2001).
   PubMedGoogle Scholar
• Villa LL, Costa RL, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer95(11), 1459–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet367(9518), 1247–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Sasieni P, Davies P et al. A systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions. Br. J. Cancer83(5), 561–565 (2000).
   PubMedGoogle Scholar
• Lörincz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cytology in cervical screening programs. Arch. Pathol. Lab. Med.127(8), 959–968 (2003).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Buntinx F, Van Ranst M et al. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J. Natl Cancer Inst.96(4), 280–293 (2004).
   PubMed Web of Science ®Google Scholar
• Arbyn M, Paraskevaidis E, Martin Hirsch P et al. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol. Oncol.99(3 Suppl. 1), S7–S11 (2005).
   PubMed Web of Science ®Google Scholar
• Nobbenhuis MA, Meijer CJ, van den Brule AJ et al. Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br. J. Cancer84(6), 796–801 (2001).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer119(5), 1095–1101 (2006).
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Koliopoulos G, Martin Hirsch P et al. Management of minor cervical cytological abnormalities: a systematic review and a meta-analysis of the literature. Cancer Treat. Rev.33(6), 514–520 (2007).
   Google Scholar
• Safaeian M, Solomon D, Wacholder S et al. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance. Obstet. Gynecol.109(6), 1325–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Sasieni P, Cuzick J. Could HPV testing become the sole primary cervical screening test? J. Med. Screen.9(2), 49–51 (2002).
   PubMed Web of Science ®Google Scholar
• Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet362(9399), 1871–1876 (2003).
   PubMed Web of Science ®Google Scholar
• Davies P, Arbyn M, Dillner J et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int. J. Cancer118(4), 791–796 (2006).
   PubMedGoogle Scholar
• Mayrand MH, Duarte-Franco E, Coutlée F et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int. J. Cancer119(3), 615–623 (2006).
   Google Scholar
• Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med.357(16), 1579–1588 (2007).
   PubMed Web of Science ®Google Scholar
• Nieminen P, Vuorma S, Viikki M et al. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. BJOG111(8), 842–848 (2004).
   PubMed Web of Science ®Google Scholar
• Kotaniemi-Talonen L, Nieminen P, Anttila A et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br. J. Cancer93(8), 862–867 (2005).
   PubMed Web of Science ®Google Scholar
• Anttila A, Ronco G, Clifford G et al. Cervical cancer screening programmes and policies in 18 European countries. Br. J. Cancer91(5), 935–941 (2004)
   PubMed Web of Science ®Google Scholar
• Ronco G, Segnan N, Giorgi-Rossi P et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl Cancer Inst.98(11), 765–774 (2006).
   PubMed Web of Science ®Google Scholar
• Ronco G, Giorgi-Rossi P, Carozzi F et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl Cancer Inst.100(7), 492–501 (2008).
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Rozendaal L, Snijders PJ et al. POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening. Int. J. Cancer.110(1), 94–110 (2004).
   PubMed Web of Science ®Google Scholar
• Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet370(9601), 1764–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Elfgren K, Rylander E, Rådberg T et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am. J. Obstet. Gynecol.193(3 Pt 1), 650–657 (2005).
   Google Scholar
• Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med.357(16), 1589–1597 (2007).
   PubMed Web of Science ®Google Scholar
• Kitchener HC, Almonte M, Wheeler P et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br. J. Cancer95(1), 56–61 (2006).
   PubMed Web of Science ®Google Scholar
• Franco EL, Cuzick J, Hildesheim A, De Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine24(Suppl. 3), S171–S177 (2006).
   PubMedGoogle Scholar